Detecting CTE during life? Researchers identify key blood test: 'Game changer'
Published in News & Features
Detecting CTE during life may soon be possible.
That’s according to Boston University researchers, who have discovered a way to accurately detect the presence of chronic traumatic encephalopathy using only a blood test.
CTE is a neurodegenerative disease caused in part by exposure to repetitive head impacts. CTE can only be detected and diagnosed after death through examining the brain. Many former NFL players have been diagnosed with CTE after death.
“This is a game changer,” said Michael Alosco, co-director of clinical research at the BU CTE Center. “We are still in the discovery phase and it’s a small sample size, but if future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment.”
The researchers from BU and Banner Health looked at a sample of 21 former American football players who participated in BU-led research studies that involved having their blood drawn during life, and then donating their brain to the BU CTE Center Brain Bank after death.
Of the sample, 18 had CTE and three had no CTE at autopsy. Of the 18 with CTE, 16 had high stage, and two had low stage.
The researchers examined their blood for a protein called endogenously cleaved microtubule-binding region tau (eMTBR-tau) — a marker of the tau tangles that also are known to form in Alzheimer’s disease.
Blood plasma eMTBR-tau concentrations were significantly higher in participants with high-stage CTE than in those with low-stage CTE or no CTE.
“Having blood tests that accurately determine the underlying pathology, which are now approved for use, has been revolutionary in the way we diagnose patients and design therapeutic trials that aim to combat Alzheimer’s disease,” said Nicholas Ashton, senior director of Banner Health’s Fluid Biomarker Program. “With this new study, we are optimistic that the same will be true for CTE.”
Of the 21 former American football players included in the study, 12 played professional, seven played college, and two played at the high school level.
Eleven of the 12 professional, four of the seven college, and one of the two high school football players had high stage CTE. The other professional and high school football players had low stage CTE.
Blood plasma eMTBR-tau was not elevated in those with low stage CTE or no CTE, only in those with high stage CTE.
High stage CTE has been diagnosed in athletes who died as young as their early 20s, but tends to most commonly be found with older age.
Five of the cases with CTE also had Alzheimer’s disease. Plasma eMTBR-tau levels were highest among participants who had both CTE and Alzheimer’s.
Also, a second blood marker that has been widely known to detect Alzheimer’s, plasma p-tau217, was only elevated in those with Alzheimer’s.
The current study has the largest sample of participants with blood collected during life and who have an available autopsy. However, the researchers caution that the finding remains preliminary due to the small sample size, limited representation of people with low stage CTE, and lack of age-matched controls.
“While there is still much work to do to validate these findings before the test is ready to use in patients, I am very hopeful that this study marks a major milestone in our ability to diagnose and ultimately treat this devastating disease,” said Gil Rabinovici Edward, a professor in Memory and Aging from the University of California San Francisco.
Meanwhile, other researchers also found spikes of blood plasma eMTBR-tau243 in people with autopsy-confirmed CTE. The cases were different, and a different method was used to detect eMTBR-tau.
“We are excited by both sets of findings,” said Annalise Miner, a behavioral neuroscience PhD student working in Alosco’s lab at Boston University Chobanian and Avedisian School of Medicine.
“It is important for the public to know that the blood test is not currently FDA-approved, nor is it available to the public and should not be used or attempted to be used to make diagnostic decisions about CTE until validation studies are completed,” Miner added.
People concerned about their brain health should consider being evaluated by a clinician who specializes in neurodegenerative conditions. Identifying and addressing risk factors can support brain health and improve quality of life.
The subjects were participants in multiple ongoing studies funded by the National Institutes of Health, including the DIAGNOSE CTE Research Project and BANK CTE. The studies are still enrolling subjects and interested individuals should join the Concussion and CTE Foundation research registry at www.concussionandcte.org/get-involved/participate-research.
______
©2026 MediaNews Group, Inc. Visit at bostonherald.com. Distributed by Tribune Content Agency, LLC.







Comments